All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
A subsidiary of Merck & Co. Inc., of Whitehouse Station, N.J., and Eli Lilly and Co., of Indianapolis, formed an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials.